US Equities insigtX

PMGC Q3 Revenue Surges 785% YoY to $2.53 Million, Marking Fifth Consecutive Quarter of Growth

Revenue grew for the fifth consecutive quarter, with the third straight quarter of growth exceeding 90%. All five acquired companies contributed a full quarter of results for the…

Published
Market
US Equities
Source
insigtX

Revenue grew for the fifth consecutive quarter, with the third straight quarter of growth exceeding 90%. All five acquired companies contributed a full quarter of results for the first time. The balance sheet reflects the consolidation of PMGC's first sponsored SPAC, NorthStrive Acquisition Corp I, including $100.4 million in trust funds; the SPAC has since signed a definitive agreement with advanced nuclear technology company Nuclea Energy Inc. for a proposed business combination with an implied enterprise value of $350 million.

NEWPORT BEACH, Calif., November 16, 2026 — PMGC Holdings Inc., a diversified holding company, has filed its Form 10-Q quarterly report with the U.S. Securities and Exchange Commission for the three- and nine-month periods ended September 30, 2026. The quarterly report is available on the SEC's website at www.sec.gov under the company's filings.

The third quarter of 2026 was the first quarter in which every business acquired by PMGC since July 2025 contributed a full three months of revenue, with results reflecting the operational foundation the company has been building. Revenue reached approximately $2.53 million, the highest quarterly revenue in company history, while operating expenses declined 27% from the second quarter and net loss narrowed for the second consecutive quarter. During the quarter, PMGC's first sponsored special purpose acquisition company, NorthStrive Acquisition Corp I, completed its $100 million initial public offering and is now consolidated into the company's financial statements.

Q3 2026 Financial Highlights Revenue was approximately $2.53 million, up 785% from approximately $286,000 in Q3 2025 and up 94% from approximately $1.31 million in Q2 2026. Q3 2026 revenue alone exceeded the company's full-year 2025 revenue by more than four times. Gross profit was approximately $601,000, up 671% from approximately $78,000 in Q3 2025 and up 56% from approximately $386,000 in Q2 2026, marking the fifth consecutive quarter of sequential gross profit growth.

For the first nine months of 2026, A&B Aerospace, Inc. and Pacific Sun Packaging, Inc. achieved gross margins of 36.6% and 47.0%, respectively. The Q3 blended gross margin of 23.8% reflects the impact of the former AGA Precision Systems business, which was merged into A&B Aerospace in July 2026 to share personnel, facilities, and equipment and reduce duplicate overhead.

Operating expenses were approximately $3.08 million, down 27% from approximately $4.21 million in Q2 2026. Compared to Q3 2025, operating expenses grew 35% while revenue grew 785%. Net loss was approximately $2.24 million, improving 14% from approximately $2.59 million in Q3 2025 and 24% from approximately $2.94 million in Q2 2026. Net loss attributable to PMGC shareholders for Q3 2026 was approximately $2.41 million.

First nine-month revenue was approximately $4.52 million, approximately 7.7 times the company's full-year 2025 revenue of approximately $590,000. Revenue has grown for five consecutive quarters since the company completed its initial acquisitions in July 2025, with growth in every quarter, primarily driven by the acquisition of SVM Machining, Inc. in February 2026 and A&B Aerospace in May 2026:

Quarterly Revenue: Q2 2025: None; Q3 2025: $285,948; Q4 2025: $304,136; Q1 2026: $681,994; Q2 2026: $1,306,610; Q3 2026: $2,530,364
Sequential Growth: Q2 2025: N/A; Q3 2025: N/A; Q4 2025: 6%; Q1 2026: 124%; Q2 2026: 92%; Q3 2026: 94%

Balance Sheet Highlights as of September 30, 2026 Total assets were approximately $133.1 million, compared to approximately $12.87 million at December 31, 2025, and approximately $14.94 million at September 30, 2025. The increase primarily reflects the consolidation of NSAI, including approximately $100.4 million in restricted cash held in the NSAI trust account, as well as the acquisitions of SVM and A&B Aerospace. Excluding restricted cash held in the trust account, total assets were approximately $32.7 million, up 154% from year-end 2025 and up 119% year-over-year. Cash was approximately $13.0 million, up 140% from approximately $5.4 million at December 31, 2025, and up 69% from approximately $7.7 million at September 30, 2025. After a non-cash charge of approximately $4.9 million to additional paid-in capital to remeasure NSAI's public shares to their redemption value, shareholders' equity attributable to PMGC was approximately $12.1 million, up 55% from approximately $7.84 million at December 31, 2025, and up 43% from September 30, 2025.

Consolidation of NorthStrive Acquisition Corp I PMGC serves as the sponsor of NSAI through its wholly owned subsidiary NorthStrive Sponsor I LLC, and NSAI completed its $100 million initial public offering on August 19, 2026. Beginning in Q3 2026, NSAI is consolidated into PMGC's financial statements. Approximately $100.4 million in the trust account is held for the benefit of NSAI's public shareholders, constitutes restricted cash, is not available to fund PMGC's operations, and an equal amount is presented as redeemable non-controlling interests outside of total equity. Interest income of approximately $489,000 for Q3 includes approximately $423,000 earned from the trust account. The underwriters' over-allotment option in NSAI's IPO expired unexercised on October 1, 2026.

Operational Highlights Aerospace platform consolidated under A&B Aerospace. On July 2, 2026, AGA Precision Systems LLC was merged into A&B Aerospace, consolidating PMGC's aerospace precision manufacturing operations under one company to share personnel, equipment, certifications, and administrative support. A&B Aerospace, founded in 1948, holds AS9100D certification and serves long-standing Tier 1 customers including Boeing, Honeywell, and Moog, contributing approximately $2.13 million in revenue with a 36.6% gross margin from its acquisition on May 11, 2026 through September 30, 2026.

Long-term agreement with PAD Group. A&B Aerospace entered into a long-term agreement with Precision Aerospace & Defense Group, Inc., effective July 23, 2026, to manufacture precision-machined aerospace and defense components under purchase orders, including orders related to U.S. federal government prime contracts. The agreement has a two-year term with automatic one-year renewal and no guaranteed minimum purchase volumes.

Investment in automation and lights-out manufacturing. In August 2026, the company announced it had invested in advanced manufacturing equipment for its aerospace and defense manufacturing operations, including a five-axis machining center, a CNC lathe with Y-axis and driven tooling, and a Swiss-type CNC lathe with bar feeder enabling lights-out manufacturing, and is evaluating robotics and automation technologies to increase capacity and efficiency.

Specialized IT packaging. Pacific Sun provides protective packaging for semiconductors, data center, and networking hardware to more than 300 commercial customers, achieving a 47.0% gross margin in the first nine months of 2026, up from 29.1% from its acquisition in July 2025 through year-end 2025, which PMGC believes reflects improved unit economics under its ownership.

Defense technology. NorthStrive Defense Tech LLC signed a definitive exclusive worldwide license agreement with the Florida State University Research Foundation for U.S. Patent No. 12,291,334, covering multi-domain drone payload technology for aerospace and defense applications, and engaged Deploy360 to independently validate its optioned patent for drone navigation technology in GPS-denied environments.

Biosciences. NorthStrive Biosciences Inc. reported positive results from Phase 3 of its AI-driven drug discovery program with Yuva Biosciences, in which four AI-screened drug candidates increased ANT1 protein expression in primary human skeletal muscle cells, and announced an expansion plan to advance these four compounds toward lead and backup compound nomination for potential applications in heart disease and obesity. The company also announced two U.S. patent applications covering EL-22 and EL-32 for muscle loss in microgravity environments, and a statement of work with Charles River Laboratories supporting both programs.

Royalty revenue stream. In September 2026, the company announced a payment agreement with Longevity Health Holdings under which confirmed 2025 royalties of $94,937, as well as future royalties from a business divested in January 2025, will be paid to NorthStrive Biosciences in monthly installments of $10,000 beginning October 15, 2026.

Recent Developments Post-Quarter-End Developments NSAI proposed business combination with Nuclea Energy. On October 30, 2026, NSAI entered into a definitive business combination agreement with Nuclea Energy Inc., a development-stage company developing advanced nuclear technologies including the Morpheus micro modular reactor, which was announced on November 2, 2026. The agreement provides for share consideration based on a $350 million valuation of Nuclea, subject to adjustment at closing, plus up to 15 million earnout shares payable upon achievement of certain milestones. The proposed transaction is expected to close in the first half of 2027, and the agreement may be terminated if closing does not occur by April 30, 2027. Conditions to closing include approvals from NSAI and Nuclea shareholders, effectiveness of a Form S-4 registration statement, receipt of a final prospectus receipt in Canada, Nasdaq listing approval, Nuclea's completion of its pending acquisition of Moltex assets by November 30, 2026, and NSAI having at least $3.0 million in available cash at closing. As an existing investor in Nuclea, PMGC has agreed to subscribe for bonds issued by a Nuclea subsidiary in an aggregate principal amount of $1.845 million to fund the Moltex acquisition. NSAI has disclosed substantial doubt about its ability to continue as a going concern if it does not complete a business combination by August 19, 2027. There can be no assurance the proposed transaction will be completed.

EL-32 preclinical results. On November 5, 2026, the company announced completion of a preclinical proof-of-concept study of NorthStrive Biosciences' EL-32 in combination with semaglutide, which produced the first controlled in vivo data for EL-32 in a GLP-1 combination setting. The study found that absolute lean body mass was statistically significantly higher with the highest tested dose of EL-32 combined with semaglutide compared to semaglutide alone. The findings are preliminary and limited to specific metrics and doses; the combination did not show consistent additive metabolic benefits over semaglutide alone, and EL-32 alone did not show meaningful improvements. The contract research organization noted that the semaglutide dose used left a limited window to detect additional effects of EL-32, and NorthStrive Biosciences plans to design a follow-up preclinical study using a lower dose of semaglutide with lean body mass and body composition as primary endpoints.

Investment in Orbit2Orbit. Following a non-binding term sheet announced in August 2026, PMGC Capital LLC completed a subscription for ordinary shares of Orbit2Orbit Pty Ltd, an Australian space technology company developing space logistics and infrastructure, which was announced on November 10, 2026.

In the first nine months of 2026, PMGC generated approximately $4.52 million in revenue, approximately 7.7 times its full-year 2025 revenue, with quarterly revenue growing from approximately $286,000 to approximately $2.53 million for the three-month periods ended September 30, 2025, and September 30, 2026, respectively. Since July 2025, the company has completed five acquisitions and established an operational foundation in industries PMGC believes are supported by strong long-term demand: aerospace, defense, and space; medical and semiconductor manufacturing; and data center and AI infrastructure supply chains. On top of this operational foundation, PMGC is advancing defense technology and biosciences development programs and has launched a SPAC sponsorship platform. The company plans to continue investing in capacity and automation for existing businesses and pursue additional acquisitions of established, cash-flow-positive businesses, and believes it remains in the early stages of building its platform scale.

Selected Financial Information Operating Results, Three Months Ended September 30: September 30, 2026; June 30, 2026; September 30, 2025; Change vs. Q2 2026; Change vs. Q3 2025 Revenue: 2,530,364; 1,306,610; 285,948; 94%; 785% Gross Profit: 601,444; 385,691; 78,030; 56%; 671% Gross Margin: 23.8%; 29.5%; 27.3%; percentage points; percentage points Total Operating Expenses: 3,080,365; 4,212,900; 2,276,931; %; 35% Net Loss from Continuing Operations: ; ; ; narrowed 25%; narrowed 15% Net Loss: ; ; ; narrowed 24%; narrowed 14% Net Loss Attributable to PMGC Shareholders: ; ; ; narrowed 18%; narrowed 7%

Selected Balance Sheet Data: September 30, 2026; June 30, 2026; December 31, 2025; September 30, 2025
Cash: 12,981,851; 18,141,758; 5,402,333; 7,700,562
Restricted Cash Held in Trust Account: 100,422,693; N/A; N/A; N/A
Total Assets: 133,101,280; 36,564,496; 12,868,473; 14,938,018
Less: Restricted Cash Held in Trust Account: ; N/A; N/A; N/A
Total Assets Excluding Restricted Cash in Trust Account: 32,678,587; 36,564,496; 12,868,473; 14,938,018
Total Liabilities: 21,033,639; 19,827,597; 5,031,111; 6,447,363
Redeemable Non-Controlling Interests: 100,422,693; N/A; N/A; N/A
Total PMGC Holdings Inc. Shareholders' Equity: 12,109,044; 16,736,899; 7,837,362; 8,490,655 Total assets excluding restricted cash held in the trust account is a non-GAAP financial measure. The company presents this measure because the trust account is not available to fund PMGC's operations and its inclusion would affect comparability with prior-period data. The table above reconciles this measure to total assets, the most directly comparable GAAP measure. This measure should be considered supplemental to, and not a substitute for, total assets as reported under GAAP.

About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across multiple industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit

Additional Information and Where to Find It In connection with the proposed business combination between NSAI and Nuclea, NSAI intends to file relevant materials with the SEC, including a Form S-4 registration statement that will include a proxy statement/prospectus of NSAI. Investors and shareholders of NSAI are urged to read the registration statement and proxy statement/prospectus, when available, as well as any other relevant documents filed with the SEC, carefully in their entirety, as they will contain important information about the proposed transaction. Documents filed by NSAI with the SEC are available free of charge at the SEC's website at www.sec.gov. NSAI is a separate SEC registrant.

No Offer or Solicitation This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any securities of PMGC or NSAI, nor does it constitute a solicitation of any proxy, consent, or authorization with respect to any securities or the proposed business combination, and no sale of securities shall occur in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "plan," "potential," "will," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release, are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding our future business, future plans and strategies, projections, anticipated events and trends, the economy, regulatory activity and future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct, and the company cautions investors that actual results may differ materially from expected results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they are made. Except as required by law, the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.

Investor Relations Contact: IR@pmgcholdings.com

Original: https://www.globenewswire.com/news-release/2026/11/16/3403392/0/en/pmgc-holdings-inc-nasdaq-elab-reports-record-q3-revenue-up-785-year-over-year-to-2-53-million-and-up-94-from-previous-quarter-files-form-10-q-for-q3-2026-total-assets-of-133-1-mill.html

insigtX content is informational and educational, not investment advice.